CorMedix (CRMD) was upgraded to a Zacks Rank #2 (Buy), signaling improved optimism toward its earnings outlook. The note suggests potential near-term upside as investor sentiment shifts positive, though there are no new operating or financial figures cited.
CorMedix (CRMD) was upgraded to a Zacks Rank #2 (Buy), signaling improved optimism toward its earnings outlook. The note suggests potential near-term upside as investor sentiment shifts positive, though there are no new operating or financial figures cited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
